Status:
COMPLETED
Immunopathology of Polymyalgia Rheumatica on Shoulder Bursae's Biopsies
Lead Sponsor:
University Hospital, Brest
Conditions:
Polymyalgia Rheumatica
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
The work carried out at the Brest University Hospital on serum immunological changes in patients with polymyalgia rheumatica (PMR) (based on clinical protocols TENOR, SEMAPHORE, THEN) made it possible...
Eligibility Criteria
Inclusion
- For everyone :
- Signed consent
- Patients over 50
- Inclusion criteria :
- For case patients:
- Addressed for PMR (diagnosis OR relapse)
- Score greater than or equal to 4 (without ultrasound criteria) or greater than or equal to 6 (with ultrasound criteria), according to the ACR / EULAR 2012 criteria for polymyalgia rheumatica, and suffering from bilateral scapular pain as well as an increased CRP level .
- Thickening of more than 2mm at least one shoulder bursae in ultrasound
- DAS-PPR\> = 10
- For witnesses:
- \- Shoulder surgery scheduled for mechanical pathology
- Exclusion criteria :
- For everyone :
- MRI with Gadolinium injection in the previous month- Clinical or paraclinical signs of giant cell arteritis
- Patient under protective measure or unable to consent
- Active cancer
- Active infection
- For the cases:
- \- History of biotherapy treatment
- For witnesses:
- History of inflammatory rheumatism
- Active inflammatory rheumatism
Exclusion
Key Trial Info
Start Date :
April 7 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 13 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04727879
Start Date
April 7 2021
End Date
August 13 2022
Last Update
August 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Brest - Service de rhumatologie
Brest, France, 29200